BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 30, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 2, 2004
View Archived Issues
Gilead's HIV Franchise Strong; Earnings Top Analyst Estimates
Gilead Sciences Inc. walloped forecasts by posting second-quarter net income that was up 11 percent, thanks to the briskly selling HIV treatment Viread and the hepatitis B therapy Hepsera. (BioWorld Today)
Read More
CV Therapeutics Gets Second Ranexa SPA For Angina, ACS
Read More
Already Being Tested Against Cancer, Bryostatin Showing Promise In Alzheimer's Fight
Read More
NAS Report On GM Foods Welcomed By Industry, BIO
Read More
Other News To Note
Read More